Interpace Biosciences Presented Two New Posters at the 2025 American Thyroid Association® (ATA) Annual Meeting

Highlights

Independent institutional experience shows archival cytology slides enabled successful molecular results in cases previously insufficient for testing by another commercially available molecular diagnostic test, helping avoid repeat FNAs
Large real-world analysis (n=28,144) demonstrates how ThyGeNEXT^® + ThyraMIR^®v2 refines risk in Bethesda III/IV nodules, especially in RAS-like and mutation-negative cases
Presentations were held during the ATA Annual Meeting, September 10–14, 2025, at the Westin Kierland in Scottsdale, Arizona

PARSIPPANY, NJ, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) presented two new scientific posters at the 2025 American Thyroid Association^® (ATA) Annual Meeting in Scottsdale, Arizona, September 10–14, 2025.

The first poster, “Utilizing Archival Cytology Slides to Overcome Molecular Testing Insufficiency Rates in Cytologically Indeterminate Thyroid Nodules: An Institutional Experience” (Poster #478), led by Temma Kaufman, MD (Associated Pathologists PA, BayCare St. Joseph’s Hospital), described a hospital-system-wide quality-improvement effort. Among 65 thyroid FNA cases previously deemed insufficient for another testing platform, 56 (86%) yielded successful molecular results using Interpace’s ThyGeNEXT^® + ThyraMIR^®v2 testing from archival cytology slides—supporting fewer repeat FNAs and streamlined workflows. View Poster

The second poster, “Refined Risk Stratification of Bethesda III/IV Thyroid Nodules Using ThyGeNEXT^® and ThyraMIR^®v2” (Poster #477), reported outcomes from 28,144 indeterminate (Bethesda III/IV) nodules tested between September 2022 and April 2025. ThyGeNEXT identified BRAF V600E-like alterations in ~4%–6% and RAS-like alterations in ~19%, while 76%–77% were mutation-negative. Subsequent ThyraMIRv2 microRNA profiling further stratified malignancy risk within both RAS-like and mutation-negative groups (e.g., >90% of mutation-negative nodules classified as low risk), enabling more precise clinical decision-making. View Poster

“These data continue to validate the real-world utility of our combination platform,” said Tom Burnell, PhD, President & Chief Executive Officer of Interpace Biosciences. “The independent institutional experience highlights practical advantages—like testing from archival cytology slides—that can reduce repeat procedures, while our 28,000-plus case analysis demonstrates how integrating DNA mutations with microRNA expression refines risk where clinicians need it most.”

“Across our health system, moving to a platform that accepts archival cytology slides made a meaningful difference,” said Temma Kaufman, MD, Associated Pathologists PA, BayCare St. Joseph’s Hospital. “We were able to obtain actionable molecular results in many cases that were initially insufficient by another testing method, helping us avoid additional FNAs and provide clearer guidance for patient care.”

About ThyGeNEXT and ThyraMIRv2

Interpace’s unique combination platform integrates next-generation DNA/RNA mutation analysis (ThyGeNEXT) with proprietary microRNA pairwise expression profiling (ThyraMIRv2) to refine malignancy risk—particularly in RAS-like and mutation-negative indeterminate nodules—supporting more informed clinical decisions.

About Interpace Biosciences

Interpace Biosciences is an emerging leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications.

Clinical services, through Interpace Diagnostics, provide clinically useful molecular diagnostic tests and bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. Interpace has two commercialized molecular tests: ThyGeNEXT for the diagnosis of thyroid cancer from thyroid nodules utilizing a next-generation sequencing assay and ThyraMIRv2, used in combination with ThyGeNEXT, for the diagnosis of thyroid cancer utilizing a proprietary microRNA pairwise expression profiler along with algorithmic classification.

For more information, please visit Interpace Biosciences’ website at www.interpace.com.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to the Company’s future financial and operating performance. The Company has attempted to identify forward-looking statements by terminology including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company’s control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to be materially different from those expressed or implied by any forward-looking statements, including, but not limited to, the possibility that the Company’s estimates of future revenue, cash flows and adjusted EBITDA may prove to be materially inaccurate, the Company’s prior history of operating losses, the Company’s ability to adequately finance its business and seek alternative sources of financing, the Company’s ability to repay borrowings from BroadOak, the Company’s dependence on sales and reimbursements from its clinical services, the Company’s ability to retain or secure reimbursement including its reliance on third parties to process and transmit claims to payers and the adverse impact of any delay, data loss, or other disruption in processing or transmitting such claims, the Company’s revenue recognition being based in part on estimates for future collections which estimates may prove to be incorrect, and the Company’s ability to restructure itself in light of the loss of reimbursement for its PancraGEN product.

Additionally, all forward-looking statements are subject to the “Risk Factors” detailed from time to time in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as amended, Current Reports on Form 8-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Contacts:

Investor Relations
Interpace Biosciences, Inc.
(855)-776-6419
Info@Interpace.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.